Immunotherapies targeting the programmed cell death-1/programmed cell death-ligand 1 pathway have emerged as promising therapeutic strategies for lung cancer. However, the expression pattern and prognostic implications of programmed cell death-ligand 1 and 2 and programmed cell death-1 in comparison with the histology and genetic alterations in pulmonary adenocarcinomas remains unclear and thus were addressed here. Programmed cell death-ligand 1 and 2 expression in tumor cells and the quantities of programmed cell death-1 + and CD8 + tumor-infiltrating lymphocytes were immunohistochemically evaluated in 497 resected pulmonary adenocarcinomas and analyzed according to clinicopathological and genetic statuses. Programmed cell death-ligand 1 and 2 expression were observed in 59% and 64% of pulmonary adenocarcinomas, respectively, and showed a strong positive correlation with each other (Po 0.001). Programmed cell death-ligand 1 expression was higher in nodal metastasis cases (P = 0.006), smokers (P = 0.056), poorly differentiated tumors and histologic subtypes of solid and micropapillary patterns (Po0.001). There was no significant difference in programmed cell death-ligand 1 and 2 expression according to EGFR mutation status. However, programmed cell death-ligand 1 expression was correlated with ALK translocation (P = 0.054) and expression of EGFR and MET (Po 0.001). Meanwhile, programmed cell death-ligand 2 expression was correlated with ALK translocation (P = 0.052), and expression of MET (Po 0.001) and ERBB2 (P = 0.013). The numbers of CD8 + and programmed cell death-1 + lymphocytes were higher in smokers (P = 0.012 and 0.016) and MET-expressing adenocarcinomas (Po 0.001). Patients expressing programmed cell death-ligand 1 and/or high ratios of programmed cell death-1 + /CD8 + lymphocytes showed shorter disease-free survival (P = 0.001). Our study demonstrated that programmed cell death-ligand 1 and 2 expression varied with histology, EGFR, ALK, MET, and ERBB2 statuses, and activation of the programmed cell death-1/programmed cell death-ligand 1 pathway may be a poor prognostic factor in pulmonary adenocarcinomas.
Non-small-cell lung cancer is the most common cause of cancer-related death worldwide. 1 The management of patients with pulmonary adenocarcinomas has shifted toward personalized therapy based on the genetic status of tumor cells. [2] [3] [4] However, there are some clinical limitations. For example, resistance to molecular targeted therapies develops in most patients eventually. 5 In addition, alternative treatment modalities, other than cytotoxic chemotherapy, are needed for pulmonary adenocarcinoma patients without druggable molecular alterations. To solve these issues, other strategies for pulmonary adenocarcinoma need to be established, and recently cancer immunotherapy has emerged as a promising therapeutic strategy.
Cancers evade host immune surveillance in diverse ways. A representative mechanism is utilization of the immune checkpoint pathway 6 that generally refers to a variety of inhibitory interactions between T cells and antigen-presenting cells or host cells. Physiologically, this pathway contributes to the maintenance of self-tolerance and control of immune responses, thereby preventing autoimmunity and harmful tissue damage. 6, 7 However, tumor cells also harness immune checkpoints to evade the immune system, including the CD80 or CD86/ CTLA4 pathway and the programmed cell deathligand 1 or 2/programmed cell death-1 that suppresses antitumor immune responses. 6, 8 Blockade of these immune checkpoints has been shown to enhance antitumor immune surveillance in vivo 9 that led to the development of therapeutic reagents targeting several immune checkpoints. Among them, antagonizing anti-CTLA4 monoclonal antibodies were developed and approved for the treatment of advanced malignant melanoma patients by the US Food and Drug Administration. 10 Alternatively, the programmed cell death-1/programmed cell death-ligand pathway has been suggested as a feasible immune checkpoint to inhibit tumor growth in vivo, 11 as programmed cell death-1 (PD-1; encoded by PDCD1 gene) attenuates immune responses by inhibiting effector T-cell proliferation and functions. [6] [7] [8] The PDCD1 ligands, programmed cell death-ligand 1 (PD-L1; also called B7-H1 and encoded by CD274 gene) or programmed cell death-ligand 2 (PD-L2; also called B7-DC and encoded by PDCD1LG2 gene), have distinct expression patterns in various tissues. PD-L1 is broadly expressed in immune and nonimmune cells, whereas PD-L2 expression is limited to activated macrophages, suggesting that PD-L1 plays an important role in peripheral immune tolerance. [6] [7] [8] 12 During chronic viral infection, interaction between PD-1 and PD-L1 or PD-L2 leads to T-cell exhaustion that is reversed by blockade of PD-1 or programmed cell death-1 ligands (PD-Ls). 6, 8, 13 Furthermore, PD-1 + T cells were observed in tumor tissues and were functionally impaired upon engagement by PD-L1 or PD-L2. [14] [15] [16] As with CTLA-4, blockade of the PD-1/PD-L pathway enhanced antitumor immune responses by restoring T-cell functions. 11 Consistently, blockade of PD-1 or PD-L1 controlled the progression of various cancers and prolonged the survival of advanced pulmonary adenocarcinoma patients in clinical trials. [17] [18] [19] Thus, immunotherapy targeting the PD-1/PD-L1 pathway has emerged as a highly promising therapeutic strategy for pulmonary adenocarcinoma. 13, [17] [18] [19] Recent studies reported that PD-1/PD-L expressions were associated with the clinicopathological features and genetic alterations of pulmonary adenocarcinoma. However, these results were conflicting. [20] [21] [22] Thus, we addressed this issue in this study using a large cohort. Our study demonstrated that PD-L1 and PD-L2 expression varied with the histology and genetic alteration status and that PD-L1 expression and a high ratio of PD-1 + /CD8 + tumor-infiltrating lymphocytes were prognostic factors associated with poor outcomes in patients with pulmonary adenocarcinoma.
Materials and methods

Patients and Samples
We collected tissues from 497 patients with pulmonary adenocarcinoma who underwent surgery and had been followed up at Seoul National University Hospital (Seoul, Republic of Korea) from 2001 to 2011. None had received chemotherapy before surgery or had distant metastasis at the time of diagnosis. Clinicopathologic data and pathologic tumor-nodemetastasis (TNM) staging from the 7th American Joint Committee on Cancer were obtained from medical and pathologic records. Tumors were histologically classified according to the 2011 International Association for the Study of Lung Cancer/the American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) classification system that includes lepidic, acinar, papillary, micropapillary, and solid predominant pattern. 23 In this study, adenocarcinoma in situ and minimally invasive adenocarcinoma were classified as adenocarcinoma with lepidic predominant pattern. The histologic grades were also performed based on the predominant patterns in the tumor: well differentiated (lepidic predominant), moderately differentiated (acinar or papillary predominant), and poorly differentiated (solid and micropapillary predominant). A tissue microarray was constructed from 2-mm diameter cores derived from representative tumor areas of formalin-fixed, paraffinembedded tissue blocks. This study followed the World Medical Association Declaration of Helsinki recommendations and was approved by the Institutional Review Board of Seoul National University Hospital (H-1404-100-572).
controversial. [24] [25] [26] Thus, to determine the appropriate antibody to evaluate PD-L1 expression, we tested staining patterns of several commercially available antibodies against PD-L1 in human placenta and Epstein-Barr virus-positive nasopharyngeal carcinoma. A rabbit anti-PD-L1 (E1L3N) XP monoclonal antibody (Cell Signaling Technology, Danvers, MA, USA) showed the appropriate specificity and sensitivity with a clear membranous and/or cytoplasmic staining pattern and used in this study (Supplementary Figure S1) . Mouse anti-PD-L2 monoclonal antibody (clone 176611, R&D Systems, Minneapolis, MN, USA), mouse anti-PD-1 monoclonal antibody (clone MRQ-22, Cell Marque, Rocklin, CA, USA), rabbit monoclonal antibody against C-MET (SP44) (catalog no. 7904430), EGFR (clone 3C6, no. 7902988), and ERBB2 (clone 4B5) (Ventana Medical Systems, Tucson, AZ, USA) were also used. Immunohistochemistry was performed using the Benchmark XT autostainer (Ventana Medical Systems). The Bond-Max automated immunostainer (Leica Microsystems, Melbourne, Australia) was used for immunohistochemistry of CD8 (rabbit IgG, clone SP16, Thermo Scientific Fischer, Rockford, IL, USA).
The PD-L1 and PD-L2 immunohistochemistry were evaluated based on the intensity and proportion of membranous and/or cytoplasmic staining in tumor cells and scored as follows: 0, negative; 1, weak or moderate in o 10% of tumor cells; 2, moderate in ≥ 10% of tumor cells; 3, strong (more intense than alveolar macrophages for PD-L1 and than tonsils for PD-L2) in ≥ 10% of tumor cells. Cases with scores of 2 or 3 were deemed positive for PD-L1 or PD-L2 expression. Alternatively, the membranous staining of PD-L1 and PD-L2 was evaluated. Cases showing complete or incomplete membranous staining in ≥ 5% of tumor cells with moderate (score 2) to strong (score 3) intensity were considered to be positive for PD-L1 or PD-L2 membranous expression.
Immunohistochemistry for EGFR and MET was assessed by modified criteria of previous report. 27 Cases were scored into 0 (absent or only focal weak), 1 (weak to moderate in ≤ 40% of tumor cells), 2 (weak to moderate in ≥ 40% of tumor cells), and 3 (strong in ≥ 10% of tumor cells); and then classified into negative (score 0 or 1) and positive (score 2 or 3) for EGFR and MET expression. ERBB2 expression was scored from 0 to 3+ according to the FDAapproved guidelines for the HercepTest and cases with scores of 2+ or 3+ were considered positive for expression. 28 In brief, cases with separate green and red signals and/or isolated red signals in ≥ 15% of tumor cells were considered to harbor an ALK translocation. EGFR gene copy number was estimated using an LSI EGFR SpectrumOrange/CEP7 SpectrumGreen probe set (Abbott Molecular) and interpreted according to the University of Colorado Cancer Center system as described previously. 29 Briefly, cases with high polysomy (≥4 copies of the EGFR gene in ≥ 40% of tumor cells) or gene amplification were deemed to be EGFR FISH positive. MET gene copy number was estimated using an LSI MET SpectrumRed/CEP7 SpectrumGreen probe (Abbott Molecular) and interpreted using the above University of Colorado Cancer Center system or Cappuzzo criteria (high MET gene copy number; mean ≥ 5 copies per cell) as described previously. 30 
EGFR and KRAS Mutation Analysis
Representative hematoxylin and eosin (H&E)-stained slides were reviewed and tumor regions were manually microdissected from consecutive formalin-fixed, paraffin-embedded tissue sections. After deparaffinization, genomic DNA was extracted and subjected to nested-PCR amplification of EGFR exons 18-21 and KRAS exon 2. PCR products were purified and subjected to direct Sanger sequencing using an ABI-PRISM 3100 DNA Analyzer (Applied Biosystems, Vernon Hills, IL, USA) as described previously. 31 
Statistical Analysis
All statistical analyses were performed using SPSS software (version 21; SPSS, Chicago, IL, USA). In analysis of concordance between the immunohistochemistry patterns from two separate tissue microarray sets, significance of κ-value was considered as follows: value ≤ 0.40, poor to fair concordance; 0.41-0.60, moderate concordance; 0.61-0.80, substantial concordance; 0.81-1.00, almost perfect concordance. 32 Comparisons between variables were performed using the χ 2 test, Fisher's exact test, or Student's t-test. Multivariate logistic regression analysis was used to examine predictive factors with consideration of collinearity. Cutoff values of PD-1 + and CD8 + tumor-infiltrating lymphocyte numbers and of PD-1 + /CD8 + cell ratios were determined based on the receiver operating characteristic curve at the highest positive likelihood point for disease-free survival. Disease-free survival was defined as the period between the time of surgery and that of recurrent or metastatic disease. Survival analysis was performed using the KaplanMeier method with log-rank test and multivariate Cox regression analysis. Two-sided P-values of o 0.05 were considered statistically significant.
Results
Analysis of PD-L1 and PD-L2 Expression and PD-1 + or CD8 + Tumor-Infiltrating Lymphocyte Numbers in Pulmonary Adenocarcinomas Using Immunohistochemistry
The expression of PD-L1 and PD-L2 was observed in 59% (293/497) and 64% (316/497) of pulmonary adenocarcinomas in tumor cells ( Figure 1a and Table 1 ). PD-L1 expression was scored as 3 in 8% (40/497) and as 2 in 51% (253/497) of cases, whereas PD-L2 expression was scored as 3 in 15% (72/497) and as 2 in 49% (244/497). Overall, there was a significant positive correlation between PD-L1 and PD-L2 expression (P o 0.001; Figure 1c ). When considering the membranous staining only, the PD-L1 and PD-L2 expressions were 58 and 66% of cases, showing substantial (κ = 0.739) and almost perfect agreement (κ = 0.863) with the data based on membranous and/or cytoplasmic staining (Supplementary Table S1 ). These results indicate that the concordance of two different interpretations of staining pattern, membranous/cytoplasmic staining vs only the membranous staining, was high in the PD-L1 and PD-L2 immunohistochemistry. However, the frequencies of cases with score 3 of membranous staining only were lower (4% for PD-L1 and 11% for PD-L2) than those of membranous/cytoplasmic staining. Meanwhile, it seems that immunohistochemistry analysis for PD-Ls in pulmonary adenocarcinomas has some limitation because of core-to-core variability of tissue microarray. To address this, we compared PD-L1 and PD-L2 immunohistochemistry patterns in two separate tissue microarrays using different cores from individual tumors. Our comparative analysis revealed that κ-values for PD-L1 and PD-L2 immunohistochemistry in two tissue microarrays were 0.693 and 0.669, respectively, indicating that concordance of immunohistochemistry patterns in two separate sets of tissue microarray was substantial in terms of expression patterns of PD-Ls in pulmonary adenocarcinomas.
The numbers of PD-1 + and CD8 + tumor-infiltrating lymphocytes per unit area (mm 2 ) ranged from 0 to 284 (mean 26.47) and 0 to 851 (mean 136.39), respectively, and were correlated positively with each other (r = 0.383, P o 0.001; Supplementary Figure S2) . Furthermore, the ratio of PD-1 + /CD8 + tumor-infiltrating lymphocytes was slightly higher in adenocarcinomas with PD-L1 expression than in those without PD-L1 expression (P = 0.066; Figure 2a ), whereas the numbers of PD-1 + and CD8 + tumor-infiltrating lymphocytes were not different according to the PD-L1 or PD-L2 expression (Figure 2a and Supplementary Table S1 ). These results suggest that PD-1-expressing CD8 + tumorinfiltrating lymphocytes might be relatively higher in PD-L1-positive pulmonary adenocarcinomas.
Comparative Analysis of PD-L1 and PD-L2 Expression with Clinicopathological Features and Genetic Alteration Status in Pulmonary Adenocarcinomas
The correlations between the expressions of PD-L1 and PD-L2 and the clinicopathologic features and genetic alteration status of pulmonary adenocarcinomas are summarized in Table 1 and Supplementary Table S2 , and these were similar according to membranous vs membranous/cytoplasmic immunohistochemistry patterns of PD-Ls. In brief, PD-L1 was more frequently expressed in pulmonary adenocarcinomas from smokers vs never-smokers (64% PD-1 and PD-L1 in pulmonary adenocarcinoma vs 56%, P = 0.056). PD-L1 expression was significantly higher among patients with lymph node (LN) metastasis than those without nodal metastasis (69% vs 55%, P = 0.006). Of note, PD-L1 expression rates were closely related with the histologic patterns and grades of tumors; 39% in lepidic predominant welldifferentiated adenocarcinomas, 58% in acinar or papillary predominant moderately differentiated adenocarcinomas, and 76% in solid or micropapillary predominant poorly differentiated adenocarcinomas (P o 0.001). In contrast, PD-L2 expression was not significantly different in pulmonary adenocarcinomas according to smoking status, TNM stage, or histologic pattern and grade.
PD-L1 expression (scores 2 and 3) rate was not statistically different between adenocarcinomas harboring wild-type EGFR and those harboring an EGFR mutation (Table 1) . However, a strong PD-L1 expression (score 3) was more frequently observed in adenocarcinomas with wild-type EGFR (12%) than in those with mutated EGFR (5%, P = 0.022; Figure 1d ). Meanwhile, 74% of adenocarcinomas with ALK translocation but 58% of those without ALK translocation expressed PD-L1 (P = 0.054; Table 1 ). In particular, adenocarcinomas with ALK translocation tended to exhibit a strong PD-L1 expression more frequently than those without ALK translocation (13% vs 8%, P = 0.107; Figure 1e ). Furthermore, PD-L1 expression showed a significant positive correlation with EGFR expression (68% vs 50%, P o 0.001), MET expression (75% vs 52%, P o 0.001), and MET FISH-positive status (67% vs 56%, P = 0.037; Table 1 and Figure 1f) . Meanwhile, PD-L2 expression was also more common in adenocarcinomas harboring ALK translocation (P = 0.052) and significantly higher in those showing MET (P o 0.001) and ERBB2 expression (P = 0.013; Table 1 ). Logistic regression analysis (for variables including gender, age, smoking, tumor size, LN metastasis, histology, a ratio of PD-1 + /CD8 + tumor-infiltrating lymphocytes, EGFR mutation, ALK translocation, and expressions of EGFR, MET, ERBB2, and PD-L2) revealed that histology and expression of MET, EGFR, and PD-L2 were significant parameters independently affecting PD-L1 expression in pulmonary adenocarcinomas ( Table 2) .
Comparative Analysis of PD-1 + and CD8 + Tumor-Infiltrating Lymphocyte Numbers with Clinicopathological Features and Genetic Alteration Status in Pulmonary Adenocarcinomas
Comparative analysis of the numbers of PD-1 + and CD8 + tumor-infiltrating lymphocytes and the PD-1 + / CD8 + tumor-infiltrating lymphocyte ratio with clinicopathological features and genetic status is detailed in Supplementary Table S3 , and the representative results are displayed in Figure 2 . In brief, higher numbers of CD8 + cells were detected in adenocarcinomas ≤ 3 cm than in those > 3 cm (P = 0.007; Figure 2c ) and in smokers than in neversmokers (P = 0.012; Figure 2b ). PD-1 + cells were also greater in number in adenocarcinomas ≤ 3 cm (P = 0.05; Figure 2c ) and in smokers (P = 0.016; Figure 2b ). Of note, significantly higher numbers of PD-1 + and CD8 + tumor-infiltrating lymphocytes were found in MET expression-positive adenocarcinomas compared with MET expression-negative cases (P o 0.001 for both; Figure 2d and Supplementary Table S3 ). Numbers of CD8 + cells were high in well-differentiated tumors, intermediated in moderately differentiated tumors, and low in poorly differentiated tumors. However, there was no significant difference in the numbers of PD-1 + cells according to the histologic grade.
Prognostic Significance of PD-L1 and PD-L2 Expressions and PD-1 + and CD8 + Tumor-Infiltrating Lymphocyte Numbers in Pulmonary Adenocarcinomas
In univariate survival analysis, alleged prognostic factors including stage, tumor size, and LN metastasis were significantly associated with disease-free survival in patients with pulmonary adenocarcinoma (all P o 0.001; data not shown). PD-L1, but not PD-L2, expression was significantly correlated with poor disease-free survival (P = 0.030; Figure 3a) . Membranous PD-L1, but not PD-L2, expression also showed a significant association with shorter diseasefree survival (P = 0.018; Supplementary Figure S3) . A high number of PD-1 + or CD8 + tumor-infiltrating lymphocytes was associated with significantly prolonged disease-free survival (P = 0.025 and 0.003, respectively; Figure 3b and c). However, a higher ratio of PD-1 + /CD8 + tumor-infiltrating lymphocytes (defined as ≥ 0.25) was associated with a much shorter disease-free survival (P = 0.013; Figure 3d ). Moreover, patients with PD-L1 expression and/or high PD-1 + /CD8 + tumor-infiltrating lymphocyte ratio displayed significantly shorter disease-free survival compared with those lacking PD-L1 expression and showing a low PD-1 + /CD8 + tumor-infiltrating lymphocyte ratio (P = 0.001; Figure 3e ). Similarly, the combination of PD-L2 expression and/or a high PD-1 + /CD8 + tumor-infiltrating lymphocyte ratio was also correlated with shorter disease-free survival (P = 0.046; Figure 3f ). Multivariate analysis including gender, age, histologic grade, stage, combined PD-L1 expression and/or PD-1 + /CD8 + tumor-infiltrating lymphocyte ratio, and PD-L2 expression as variables revealed that histologic grade (well-differentiated (reference) vs moderately to poorly differentiated; odds ratio (OR), 2.486; 95% confidence interval (CI), 1.204-5.134; P = 0.014), stage (I (reference) vs II-III; OR, 2.289; 95% CI, 1.481-3.538; P o 0.001), and combined PD-L1 expression and/or PD-1 + /CD8 + tumorinfiltrating lymphocyte ratio (no PD-L1 expression and low PD-1 + /CD8 + tumor-infiltrating lymphocyte ratio (reference) vs others; OR, 1.771; 95% CI, 1.168-2.687; P = 0.007) were independent prognostic factors for disease-free survival.
Discussion
Our study demonstrated that PD-L1 and PD-L2 were variably expressed in pulmonary adenocarcinomas according to the histologic pattern and genetic alteration status. The expression rate of PD-L1 in pulmonary adenocarcinomas was ∼ 60%, and this was higher compared with several previous studies, 20, 25 but lower compared with a very recent study. 22 This might be attributable to the use of different antibodies and interpretation criteria in the lack of consensus PD-L1 immunohistochemistry method at present. In this study, PD-L1 and PD-L2 expression determined by immunohistochemistry in pulmonary adenocarcinomas were closely correlated with each other. This observation was consistent with the mRNA expression data from 129 pulmonary adenocarcinomas archived in The Cancer Genome Atlas (http://tcga-data.nci.nih.gov/tcga/) (P o 0.001). Moreover, pulmonary adenocarcinomas expressing PD-L1 tended to have higher PD-1 + /CD8 + tumorinfiltrating lymphocyte ratio than PD-L1-negative tumors. These findings suggest that PD-L1 expression by pulmonary adenocarcinomas might be involved in immune regulation via the PD-1/PD-L1 pathway within the tumor microenvironment.
Previously, several studies demonstrated the PD-L1 expression patterns in both adenocarcinoma and squamous cell carcinoma of the lung. [20] [21] [22] 25 However, only a few studies performed analysis on the PD-L1 expression according to the histologic classification of pulmonary adenocarcinomas using IASLC/ATS/ERS (2011) system. 20, 33 Our study showed that PD-L1, but not PD-L2, expression was significantly and independently associated with histologic grades of pulmonary adenocarcinomas. Given that poorly differentiated pulmonary adenocarcinomas usually show more aggressive behavior than well-differentiated ones and PD-L1 expression in tumor cells may exert immune evasion of cancers, it is suggested that high PD-L1 expression may be one of the candidates to explain progression and aggressive biologic behavior of pulmonary adenocarcinomas with poor differentiation.
Both intrinsic and extrinsic mechanisms contribute to induction of PD-L1 (CD274) expression in tumor cells. 6, 34 During antitumor immune responses in vivo, various immune and tumor cells produce cytokines that upregulate PD-L1 (CD274) extrinsically in a paracrine and/or autocrine manner. 6, 35 In contrast, an intrinsic mechanism refers to constitutive PD-L1 expression by oncogenic signaling, such as NPM-ALK translocation, PI3K/Akt activation, or chronic viral infection, 26, 34, 36 suggesting that intrinsic genetic alterations in tumor cells might account for regulation of the PD-1/PD-L pathway. Moreover, several driver mutations have emerged as therapeutic targets for patients with pulmonary adenocarcinoma. Thus, comparative evaluation between the PD-1/PD-L1, PD-L2 pathway, and genetic alterations in pulmonary adenocarcinomas may have clinical relevance. Our study demonstrated that PD-L1 and PD-L2 expression varied based on the EGFR, ALK, MET, and ERBB2 statuses in pulmonary adenocarcinomas.
Recently, it was demonstrated that overexpression of PD-L1 could be induced in tumor cells showing resistance to targeted therapies against BRAF and EGFR. 15, 37 However, it has also been reported that PD-L1 expression was not associated with EGFR, KRAS, or BRAF mutation or ALK translocation. 20 In contrast, other studies reported that PD-L1 overexpression was associated with EGFR mutation in non-small-cell lung cancer. 21, 22 In this study, although a strong expression of PD-L1 was more common in pulmonary adenocarcinomas with wild-type EGFR, there was overall no significant difference in PD-L1 expression according to EGFR mutation status. This was comparable to previous in vitro studies demonstrating that EGFR pathway activation triggered upregulation of PD-L1 in lung cancer cells in an EGFR mutation-independent manner, and that PD-L1 (CD274) mRNA levels were not statistically different between lung cancer cell lines harboring and lacking EGFR mutation. 15 Meanwhile, a strong positive correlation between EGFR with PD-L1 expression observed in this study hints that the EGFR pathway might contribute to the upregulation of PD-L1 in pulmonary adenocarcinomas. Of note, patients with ALK translocation tended to show high expression of both PD-L1 and PD-L2 in pulmonary adenocarcinomas. Consistent with this, ALK activity by NPM-ALK translocation induced PD-L1 (CD274) expression in T-cell lymphoma. 34 Thus, these results imply that ALK translocation might contribute to the PD-L1 and PD-L2 expression in pulmonary adenocarcinomas, although the number of patients with ALK translocation included in this study was too small for this result to reach statistical significance. In this study, PD-L1 and PD-L2 expression were significantly and independently associated with MET expression. These were correlated with The Cancer Genome Atlas lung adenocarcinoma genome data that also showed a strong tendency toward co-occurrence among CD274, PDCD1LG2, and MET mRNA expression (Po 0.001 and P = 0.027, respectively). Intriguingly, a greater number of PD-1 + or CD8 + cells infiltrated MET-positive pulmonary adenocarcinomas. MET plays an important role in the progression and aggressiveness of pulmonary adenocarcinomas via activation of oncogenic signaling pathways. 38 Thus, it is conceivable that MET may also be involved in immune evasion by regulating PD-1/PD-L pathway. Moreover, considering that MET amplification is one of the major mechanisms mediating acquired resistance to EGFR tyrosine kinase inhibitor in EGFR-mutated pulmonary adenocarcinomas, 39 it is hypothesized that MET might regulate the PD-1/PD-L1 pathway in patients resistant to EGFR tyrosine kinase inhibitor, and this should be verified by further study.
The prognostic implications of PD-Ls and PD-1 in non-small-cell lung cancer have been controversial. 25, [40] [41] [42] PD-1 and PD-L1 blockade has shown to prolong survival in patients with advanced lung cancer, 17, 18, 43 indicating that activation of the PD-1/ PD-L pathway inhibits tumor surveillance, thus implicating this pathway as an adverse prognostic factor. However, a recent study demonstrated that PD-L1 (CD274) expression at the protein and mRNA levels was associated with better clinical outcomes in patients with non-small-cell lung cancer. 25 This discrepancy may be attributed to differences in PD-L1 (CD274) detection methods and heterogeneous populations of various non-small-cell lung cancer subtypes, stages, and treatment modalities. 22 To minimize these issues, we compared the clinical features associated with disease-free survival among a large cohort of pulmonary adenocarcinoma patients who underwent surgical resection. Our study revealed that PD-L1 expression was a poor prognostic factor in patients with pulmonary adenocarcinoma. Consistent with our results, several reports claimed that elevated PD-L1 expression was predictive of poor clinical outcomes in several cancers including non-small-cell lung cancer. 41, 42 Furthermore, upon interaction with PD-1, PD-L1 contributed to an anti-apoptotic effect in tumor cells in a cytosolic domain-dependent manner, 44 indicating that PD-L1 expression in tumor cells might not only induce T-cell exhaustion but also inhibit tumor cell death. In our study, although increased number of CD8 + or PD-1 + tumor-infiltrating lymphocytes were associated with prolonged disease-free survival, a high ratio of PD-1 + /CD8 + tumor-infiltrating lymphocytes was associated with shorter diseasefree survival. Several groups demonstrated that increased CD8 + tumor-infiltrating lymphocytes and even PD-1 + tumor-infiltrating lymphocytes were a favorable prognostic factor in various types of cancers. [45] [46] [47] [48] These studies suggested that increased PD-1 + tumor-infiltrating lymphocytes may reflect a subset of immune cells previously activated by the antitumor immune response, and thereby correlated with a favorable clinical outcome. 48 However, PD-1 + T cells have been regarded as functionally exhausted rather than activated because of chronic and persistent antigenic exposure from either viral infection or the tumor microenvironment, suggesting that the PD-1 + /CD8 + tumor-infiltrating lymphocyte ratio might reflect attenuated cytotoxicity of CD8 + T cells against tumors. This suggestion may account for the clinical implication that a high PD-1 + /CD8 + tumorinfiltrating lymphocyte ratio is a poor prognostic factor for pulmonary adenocarcinomas in this study. Moreover, it has been demonstrated that the main subset of tumor-infiltrating immune cells expressing PD-1 were CD8 + rather than CD4 + T cells, [14] [15] [16] 49 supporting that PD-1 + cells in pulmonary adenocarcinomas are primarily CD8 + T cells. Thus, it is reasonable that high PD-1 + /CD8 + tumor-infiltrating lymphocyte ratios and PD-L1 expression in tumors might inhibit specific immune responses against tumor cells that may be a useful parameter for unfavorable prognosis of patients with pulmonary adenocarcinoma.
There are several important issues regarding the therapeutic application of the PD-1/PD-L1 pathway in non-small-cell lung cancer. First, the predictive biomarkers for PD-1/PD-L1-targeting immunotherapy remain unclear. In a recent clinical trial for the anti-PD-L1 antibody, MPDL3280A, PD-1/PD-L1 blockade induced objective responses in ∼ 20% of patients with advanced non-small-cell lung cancers, 17, 18 associated with PD-L1 expression levels estimated using immunohistochemistry and with smoking status. 43 Our study demonstrated that the expression of PD-L1 and PD-1 in pulmonary adenocarcinomas varied with genetic alteration status but not limited to a specific genetic subset. Thus, we hypothesize that evaluation of PD-L1 expression and/or high PD-1 + /CD8 + tumor-infiltrating lymphocyte ratio before immunotherapy may be useful in predicting responses to immunotherapy for patients with pulmonary adenocarcinoma regardless of genetic alteration status. Second, the efficiency and usefulness of PD-1/PD-L1-targeted immunotherapy as adjuvant therapy for pulmonary adenocarcinomas has not been established. Activation of the PD-1/PD-L1 pathway was associated with poor disease-free survival in pulmonary adenocarcinoma patients with postoperative status in our study, suggesting that PD-1/PD-L1-targeted therapy could be considered as an adjuvant treatment for pulmonary adenocarcinoma patients in the future.
In conclusion, PD-L1 and PD-L2 expression in pulmonary adenocarcinomas varied in terms of EGFR, ALK, MET, and ERBB2 alteration statuses, and activation of the PD-1/PD-L1, PD-L2 pathway predicted poor prognosis for pulmonary adenocarcinoma. Thus, PD-1/PD-L1, PD-L2 pathway-targeted immunotherapy may be useful for treatment of patients with pulmonary adenocarcinoma.
